TY - JOUR
T1 - Nanoparticle-mediated targeted drug delivery for breast cancer treatment
AU - Liyanage, Piumi Y.
AU - Hettiarachchi, Sajini D.
AU - Zhou, Yiqun
AU - Ouhtit, Allal
AU - Seven, Elif S.
AU - Oztan, Cagri Y.
AU - Celik, Emrah
AU - Leblanc, Roger M.
N1 - Funding Information:
This work was supported by National Science Foundation grant 011298 and National Institute of Health under Grant 009887.
Funding Information:
This work was supported by National Science Foundation grant 011298 and National Institute of Health under Grant 009887 .
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/4
Y1 - 2019/4
N2 - Breast cancer (BC) is the most common malignancy in women worldwide, and one of the deadliest after lung cancer. Currently, standard methods for cancer therapy including BC are surgery followed by chemotherapy or radiotherapy. However, both chemotherapy and radiotherapy often fail to treat BC due to the side effects that these therapies incur in normal tissues and organs. In recent years, various nanoparticles (NPs) have been discovered and synthesized to be able to selectively target tumor cells without causing any harm to the healthy cells or organs. Therefore, NPs-mediated targeted drug delivery systems (DDS) have become a promising technique to treat BC. In addition to their selectivity to target tumor cells and reduce side effects, NPs have other unique properties which make them desirable for cancer treatment such as low toxicity, good compatibility, ease of preparation, high photoluminescence (PL) for bioimaging in vivo, and high loadability of drugs due to their tunable surface functionalities. In this study, we summarize with a critical analysis of the most recent therapeutic studies involving various NPs-mediated DDS as alternatives for the traditional treatment approaches for BC. It will shed light on the significance of NPs-mediated DDS and serve as a guide to seeking for the ideal methodology for future targeted drug delivery for an efficient BC treatment.
AB - Breast cancer (BC) is the most common malignancy in women worldwide, and one of the deadliest after lung cancer. Currently, standard methods for cancer therapy including BC are surgery followed by chemotherapy or radiotherapy. However, both chemotherapy and radiotherapy often fail to treat BC due to the side effects that these therapies incur in normal tissues and organs. In recent years, various nanoparticles (NPs) have been discovered and synthesized to be able to selectively target tumor cells without causing any harm to the healthy cells or organs. Therefore, NPs-mediated targeted drug delivery systems (DDS) have become a promising technique to treat BC. In addition to their selectivity to target tumor cells and reduce side effects, NPs have other unique properties which make them desirable for cancer treatment such as low toxicity, good compatibility, ease of preparation, high photoluminescence (PL) for bioimaging in vivo, and high loadability of drugs due to their tunable surface functionalities. In this study, we summarize with a critical analysis of the most recent therapeutic studies involving various NPs-mediated DDS as alternatives for the traditional treatment approaches for BC. It will shed light on the significance of NPs-mediated DDS and serve as a guide to seeking for the ideal methodology for future targeted drug delivery for an efficient BC treatment.
KW - Bioimaging
KW - Biomarkers
KW - Breast cancer
KW - Drug delivery
KW - Nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85065061677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065061677&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2019.04.006
DO - 10.1016/j.bbcan.2019.04.006
M3 - Review article
C2 - 31034927
AN - SCOPUS:85065061677
SN - 0304-419X
VL - 1871
SP - 419
EP - 433
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 2
ER -